查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586258

儿科失神癫痫药物市场：按药物、疾病类型划分 - 全球预测 2025-2030

Childhood Absence Epilepsy Treatment Market by Drug (Lamotrigine, Valproate), Disease Type (Atypical Absence Seizures, Typical Absence Seizures) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年小儿失神癫痫药物市值为2.3776亿美元，预计2024年将达到2.5522亿美元，复合年增长率为7.43%，2030年将达到3.9281亿美元，预计将达到1000万美元。

儿童失神癫痫 (CAE) 治疗的重点是治疗这种独特形式的癫痫，其特征是频繁失神发作，主要影响 4 至 14 岁的儿童。 CAE 治疗的需求源自于其对认知发展和生活品质的潜在影响。治疗通常涉及乙舒酰亚胺、丙戊酸和拉莫三嗪等药物，旨在控制癫痫发作，同时尽量减少副作用。范围包括药品、医疗设备和辅助性治疗，最终用途为医院、专科诊所和居家照护。市场驱动因素包括意识的提高、诊断的改进以及药品技术的进步等。新型疗法和个人化医疗解决方案的开发，以及研发投资的增加，为探索有效的非侵入性治疗创造了潜在的机会。此外，医疗保健提供者和远端医疗平台科技公司之间的合作有助于扩大农村覆盖范围和持续监控。

主要市场统计
基准年[2023] 23776万美元
预测年份 [2024] 2.5522亿美元
预测年份 [2030] 3.9281亿美元
复合年增长率（%） 7.43%

儘管有这些治疗机会，市场仍面临一些挑战，包括治疗成本高、缺乏熟练的医疗保健专业人员以及长期使用治疗药物的潜在副作用。监管障碍和严格核准是新疗法快速商业化的障碍。为了克服这些挑战，鼓励相关人员投资数位监测工具，例如穿戴式装置和人工智慧驱动的诊断平台，以实现更好的癫痫发作追踪和管理。此外，基因组定序和生物标记识别的发展有可能在个人化治疗方法、最大限度地减少药物副作用和提高治疗效果方面取得突破。该市场竞争激烈，大型製药企业和新兴生物技术公司进入市场，并具有持续研发和创新的特性。 CAE 治疗市场本质上是动态的，越来越重视精准医疗和以患者为中心的方法，使其成为一个具有长期成长潜力的领域。投资稳健的临床试验和策略联盟的公司处于有利位置，可以利用这种不断变化的格局。

市场动态：快速发展的儿童失神癫痫治疗市场的关键市场洞察

供需的动态交互作用正在改变儿科失神癫痫药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 儿童癫痫和癫痫发作的盛行率上升
    • 政府对儿童失神癫痫的支持
    • 提高家长对CAE的认识
  • 市场限制因素
    • 与药物副作用相关的风险
  • 市场机会
    • 开发新药的持续研究开发活动
    • 失神发作新治疗方法的出现
  • 市场挑战
    • 缺乏有效且可耐受的初始经验性治疗方法

波特的五力：驾驭小儿失神癫痫药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对儿科失神癫痫药物市场的影响

外部宏观环境因素在塑造小儿失神癫痫药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解儿科失神癫痫治疗药物市场的竞争状况

对儿科失神癫痫药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

儿科失神性癫痫药物市场供应商的 FPNV 定位矩阵绩效评估

FPNV定位矩阵是评估儿科失神性癫痫药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为儿科失神癫痫药物市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，对儿科失神癫痫药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 儿童癫痫和惊厥盛行率上升
      • 政府对儿童失神癫痫的援助
      • 意识提升
    • 抑制因素
      • 与药物副作用相关的风险
    • 机会
      • 开发新药的持续研究和开发活动
      • 失神发作新治疗方法的出现
    • 任务
      • 缺乏有效且可接受的初始经验性治疗
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 儿童失神癫痫治疗药物市场（按药物）

  • 拉莫三嗪
  • 丙戊酸

第七章小儿失神癫痫治疗市场：依疾病类型

  • 非典型失神发作
  • 典型失神发作

第八章北美与南美小儿失神癫痫药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区小儿失神癫痫药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲儿童失神癫痫药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories Inc.
  • Ada Health GmbH
  • CENTOGENE NV
  • Clarivate
  • Dr. Reddy's Laboratories Inc.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Jazz Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Xenon Pharmaceuticals Inc.
Product Code: MRR-433AB1DC2923

The Childhood Absence Epilepsy Treatment Market was valued at USD 237.76 million in 2023, expected to reach USD 255.22 million in 2024, and is projected to grow at a CAGR of 7.43%, to USD 392.81 million by 2030.

Childhood Absence Epilepsy (CAE) treatment focuses on managing this distinct form of epilepsy characterized by frequent absence seizures predominantly affecting children aged 4-14 years. The necessity of CAE treatment arises from its potential impact on cognitive development and quality of life. Treatment typically involves medication such as ethosuximide, valproic acid, and lamotrigine, aiming to control seizures while minimizing side effects. The scope includes pharmaceuticals, medical devices, and adjunctive therapies with end-use across hospitals, specialty clinics, and homecare settings. Market insights reveal significant growth drivers, notably increased awareness, improved diagnosis, and technological advancement in pharmaceuticals. The development of novel therapeutics and personalized medicine solutions, alongside an increase in R&D investments, creates potential opportunities to explore effective non-invasive treatments. Additionally, collaborations between healthcare providers and tech companies for telemedicine platforms cater to enhanced rural reach and continuous monitoring.

KEY MARKET STATISTICS
Base Year [2023] USD 237.76 million
Estimated Year [2024] USD 255.22 million
Forecast Year [2030] USD 392.81 million
CAGR (%) 7.43%

Despite these opportunities, the market faces several challenges, including high costs of treatment, limited availability of skilled healthcare professionals, and possible side effects of long-term medication use that may restrict therapeutic adoption. Regulatory hurdles and rigid approvals create barriers to rapid commercialization of new treatments. To navigate these challenges, stakeholders are recommended to channel investments into digital monitoring tools like wearable devices and AI-powered diagnostic platforms, which promise better seizure tracking and management. Furthermore, development in genome sequencing and biomarker identification holds potential for breakthroughs in personalized treatment regimens, minimization of drug adverse reactions, and enhanced therapeutic effectiveness. The market is heavily competitive, involving key pharmaceutical giants and emerging biotechnology firms, characterized by continuous R&D and innovation. The nature of the CAE treatment market is dynamic, with a growing emphasis on precision medicine and patient-centric approaches, positioning it as a promising field for long-term growth. Businesses investing in robust clinical trials and strategic alliances are well-placed to capitalize on this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Childhood Absence Epilepsy Treatment Market

The Childhood Absence Epilepsy Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of epilepsy and seizures in children
    • Government assistance for childhood absence epilepsy
    • Increasing parents awareness about CAE
  • Market Restraints
    • Risk associated with side effects of medications
  • Market Opportunities
    • Ongoing research & development activities for novel drug developments
    • Emerging novel treatments for absence seizures
  • Market Challenges
    • Lack of efficacious and tolerable initial empirical treatment

Porter's Five Forces: A Strategic Tool for Navigating the Childhood Absence Epilepsy Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Childhood Absence Epilepsy Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Childhood Absence Epilepsy Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Childhood Absence Epilepsy Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Childhood Absence Epilepsy Treatment Market

A detailed market share analysis in the Childhood Absence Epilepsy Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Childhood Absence Epilepsy Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Childhood Absence Epilepsy Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Childhood Absence Epilepsy Treatment Market

A strategic analysis of the Childhood Absence Epilepsy Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Childhood Absence Epilepsy Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Ada Health GmbH, CENTOGENE N.V., Clarivate, Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Jazz Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Xenon Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Childhood Absence Epilepsy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Lamotrigine and Valproate.
  • Based on Disease Type, market is studied across Atypical Absence Seizures and Typical Absence Seizures.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of epilepsy and seizures in children
      • 5.1.1.2. Government assistance for childhood absence epilepsy
      • 5.1.1.3. Increasing parents awareness about CAE
    • 5.1.2. Restraints
      • 5.1.2.1. Risk associated with side effects of medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research & development activities for novel drug developments
      • 5.1.3.2. Emerging novel treatments for absence seizures
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of efficacious and tolerable initial empirical treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Childhood Absence Epilepsy Treatment Market, by Drug

  • 6.1. Introduction
  • 6.2. Lamotrigine
  • 6.3. Valproate

7. Childhood Absence Epilepsy Treatment Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Atypical Absence Seizures
  • 7.3. Typical Absence Seizures

8. Americas Childhood Absence Epilepsy Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Childhood Absence Epilepsy Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Childhood Absence Epilepsy Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Inc.
  • 2. Ada Health GmbH
  • 3. CENTOGENE N.V.
  • 4. Clarivate
  • 5. Dr. Reddy's Laboratories Inc.
  • 6. GlaxoSmithKline plc
  • 7. H. Lundbeck A/S
  • 8. Jazz Pharmaceuticals, Inc.
  • 9. Pfizer Inc.
  • 10. Sanofi S.A.
  • 11. Teva Pharmaceutical Industries Ltd.
  • 12. Xenon Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023